Abstract:Background and purpose:Serious adverse reactions may happen in the routine administration of fluorouracil (5-FU) due to individual differences, DPD is the rate-limiting enzyme in the catabolism of 5-FU, single nucleotide polymorphisms (SNPs) in DPD gene is the main reason affecting the activity of DPD, while IVS14+1 G>A accounted for about 50% of the total mutation, reports such as IVS14+1 G>A forecasting 5-FU associated adverse reactions was rare, so we retrospectively investigated the relationship between IVS14+1 G>A genotype in the dihydropyrimidine dehydrogenase (DPD) gene and 5-FU associated adverse reactions in 80 patients with locally advanced or metastatic colorectal cancer, in order to confirm the role of DPD IVS14+1 G>A genotype in predicting and reducing adverse reactions of 5-FU-based chemotherapy. Methods:Eighty patients with unresectable locally advanced or metastatic colorectal cancer were enrolled. Single nucleotide polymorphisms for DPD gene were analyzed before chemotherapy by high-resolution melting (HRM) analysis, and the plasma concentration of 5-FU was detected by high performance liquid chromatography (HPLC) after continuous infusion of 5-FU over 12 h in each cycle. The factors related to plasma concentration of 5-FU were screened by stepwise regression. The relationship between DPD IVS14+1 genotype and adverse reactions was retrospectively analyzed in 56 patients whose plasma concentrations were greater than predicted lower limit. Results:Of the 56 patients whose plasma concentration were greater than 26.83 mg/L, the predicted lower limit, the incidence of bone marrow suppression, hand-foot syndrome and diarrhea for DPD IVS14+1 mutant patients were both higher than those DPD IVS14+1 wide type ones (P=0.04, P=0.03 and P=0.04), while there were no difference in median progression free survival (mPFS) and median OS (mOS) (mPFS:7.50±0.44 months vs 8.50±0.40 months, P=0.69;mOS:21.00±1.12 months vs 20.00±1.16 months, P=0.72). Conclusion:The patients with DPD IVS14+1 G>A mutation and higher 5-FU plasma concentration need to adjust 5-FU dosage in next chemotherapy:for patients with DPD heterozygous mutation, 5-FU dose should be appropriately reduced according to last plasma concentration to reduce adverse reactions, while the homozygous ones should avoid application of 5-FU and its derivatives.

Polymorphisms of Dihydropyrimidine Dehydrogenase Gene and Clinical Outcomes of Gastric Cancer Patients Treated with Fluorouracil-Based Adjuvant Chemotherapy in Chinese Population.

The association between DPYD gene polymorphism and chemotherapeutic toxicity of 5-FU in gastric carcinoma and colonic carcinoma]

DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.

DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU

Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in Chinese Cancer Patients

Potential of dihydropyrimidine dehydrogenase genotypes in personalizing 5-fluorouracil therapy among colorectal cancer patients

Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy.

Polymorphism of Methylenetetrahydrofolate Reductase Gene is Associated with Response to Fluorouracil-Based Chemotherapy in Chinese Patients with Gastric Cancer.

Correlation Analysis of Peripheral Dpyd Gene Polymorphism with 5-Fluorouracil Susceptibility and Side Effects in Colon Cancer Patients

The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report

Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution

Relationship between Polymorphism of X-ray Repair Cross-complementing Group 1(XRCC1)Genes and Clinical Outcome of Advanced Gastric Cancer Patients Treated with DDP-based Chemotherapy

[Correlative Analysis Between Serum Dihydropyrimidine Dehydrogenase, Activity, Concentration of 5-Fluorouracil and Adverse Events in the Treatment of Advanced Gastric Cancer Patients].

Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD

IVS14+1 G>A Genotype in the Dihydropyrimidine Dehydrogenase Gene: a Predictive Marker with Fluorouracil Pharmacokinetic in Reducing Adverse Reactions of Fluorouracil-Based Chemotherapy in Patients with Local Advanced and Metastatic Colorectal Cancer

The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer: A Meta-Analysis

Gene polymorphism of 5-Fluoropyrimidine-related enzymes in cancer patients*

Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

The Effects of Genomic Polymorphisms in One-Carbon Metabolism Pathways on Survival of Gastric Cancer Patients Received Fluorouracil-Based Adjuvant Therapy

A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer